Search for: "In Re: Mylan Technologies Inc."
Results 41 - 60
of 76
Sort by Relevance
|
Sort by Date
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit… [read post]
18 Feb 2010, 10:34 am
Most notably there’s Mylan Laboratories, Inc. v. [read post]
10 Feb 2010, 4:47 pm
Mylan Pharmaceuticals Inc. [read post]
18 Dec 2009, 9:59 am
Mylan Pharmaceuticals Inc., Mylan, Inc., Matrix Laboratories Ltd. and Matrix Laboratories Inc. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with… [read post]
1 Oct 2009, 2:14 am
Mylan Pharmaceuticals, 2008 WL 3540462 (N.D.W. [read post]
9 Sep 2009, 7:14 am
– Dispute between Wyeth and Dexel (The IP Factor) EpiPen (Epinephrine) – US: King Pharmaceuticals, Meridian Medical Technology file patent infringement suit against Teva following Para IV certification (Patent Docs) Seroxat (Paroxetine) – Israel: not even sublime, just ridiculous – Israel PTO decision in Unipharm v SmithKline Beecham (America-Israel Patent Law) Stelara (Ustekinumab, anti-IL-12 antibody) – Centocor seeks review of BPAI… [read post]
2 Sep 2009, 11:22 pm
Mylan Laboratories, Inc., 2008 WL 4813311, at *6-7 (D. [read post]
6 Aug 2009, 11:24 pm
Mylan Labs., Inc., 520 F.3d 1358, 1364 (Fed. [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
9 Jan 2009, 3:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Humira (Adalimumab) – US: Bayer HealthCare files patent infringement suit against Abbott Laboratories over Humira; Abbott fires back with lawsuit claiming Bayer’s patent invalid, not infringed or unenforceable (Law360) (Law360) (Philip Brooks' Patent Infringement Updates) (Patent Baristas) Sprycel (Dasatinib)… [read post]
25 Oct 2008, 12:03 am
Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI) Cipro (Ciprofloxacin) - US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer) Lescol (Fluvastatin) - US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief) Levaquin (Levofloxacin) - UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd… [read post]
19 Sep 2008, 6:00 pm
: (Spicy IP), India: Supreme Court on exclusive marketing rights: (Spicy IP), Japan: First induced pluripotent stem (iPS) cell patent at Kyoto University: (Competitive Info), Slovenia: Supplementary protection certificates in Slovenia: (The SPC Blog), United States: Biotech/pharma lobbying scoreboard – second quarter update – part II: (Patent Docs), United States: Ferring Pharmaceuticals argues to bring down direct purchaser suits: (Law 360), United States: Transferred… [read post]
2 Aug 2008, 12:54 am
– Technological Innovation and Intellectual Property), IP and start-ups: (Technological Innovation and Intellectual Property), Innovators: Make sure your company owns the fruits of your open innovation projects: (IP Asset Maximizer Blog), It’s all about the numbers: SuperCrunchers of patent data will gain competitive advantage: (IP Asset Maximizer Blog) Events 4-9 August: Dept Science & Technology indigenous knowledge systems expo and… [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South… [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge), (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
